Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

• Status: Completed
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to just 2 of the 3 drugs that usually given to treat this infection. The three drugs used together are called albendazole (ALB), ivermectin (IVM) and diethylcarbamazine (DEC). The usual treatment in Papua New Guinea (PNG) for lymphatic filariasis are DEC and ALB. A combination of these 3 drugs has not been previously used to treat LF.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospitals Cleveland Medical Center
• Treatments: Albendazole; Diethylcarbamazine; Ivermectin

Criteria

Inclusion Criteria:

• Men and women 18-65 years

• >50 mf/ml in finger stick blood samples

• Willing to give informed consent

Exclusion Criteria:

• Prior treatment for LF within last 5 years

• Pregnant (do pregnancy test)

• Hemoglobin < 7 g/dl

• permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension

• AST/ALT and creatinine > 1.5 upper limit of normal.

• Urine dipstick with glucose ≥ 2+ and/or protein ≥ 2+